Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
Naunyn Schmiedebergs Arch Pharmacol ; 394(8): 1703-1711, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34014349

RESUMO

Crotamine is a polypeptide toxin isolated from rattlesnake venom. Although several studies have been developed identifying many biological effects of isolated crotamine, none of them evaluated its acute toxicity, antinociceptive, and anti-inflammatory activities through oral administration. All in vivo experiments from this study were performed in mice. The up-and-down procedure and hippocratic screening were carried out to evaluate possible pharmacological and toxic effects. Antinociceptive and anti-inflammatory activities of this toxin were evaluated using acetic acid-induced abdominal writhing, formalin-induced pain assays, croton oil-induced ear edema, and carrageenan-induced pleurisy. Crotamine did not cause lethality or signs of intoxication up to the maximum dose tested (10.88 mg/kg). The number of contortions was reduced significantly by 34, 57, and 74% at the oral doses of 0.08, 0.16, and 0.32 mg/kg, respectively. At the dose of 0.16 mg/kg, crotamine decreases pain time-reactivity at neurogenic phase by 45% and at inflammatory phase by 60%. Also, crotamine elicited antiedematogenic activity through the attenuation of the croton oil-induced ear edema by 77%. In the carrageenan-induced pleurisy, the leukocyte, neutrophil, and mononuclear cell migration to the lesion site were reduced by 52%, 46%, and 59%, respectively. Altogether, crotamine demonstrated in vivo antinociceptive and anti-inflammatory effect through acute oral administration, generating an anti-migratory mechanism of action at non-toxic doses.


Assuntos
Analgésicos/farmacologia , Anti-Inflamatórios/farmacologia , Venenos de Crotalídeos/farmacologia , Administração Oral , Analgésicos/administração & dosagem , Analgésicos/toxicidade , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/toxicidade , Carragenina , Venenos de Crotalídeos/administração & dosagem , Venenos de Crotalídeos/toxicidade , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Edema/tratamento farmacológico , Edema/patologia , Masculino , Camundongos , Dor/tratamento farmacológico , Pleurisia/tratamento farmacológico , Pleurisia/patologia , Testes de Toxicidade Aguda
2.
Methods Mol Biol ; 2118: 61-89, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32152971

RESUMO

Crotamine is a basic, 42-residue polypeptide from snake venom that has been shown to possess cell-penetrating properties. Here we describe the preparation, purification, biochemical and biophysical analysis of venom-derived, recombinant, chemically synthesized, and fluorescent-labeled crotamine. We also describe the formation and characterization of crotamine-DNA and crotamine-RNA nanoparticles; and the delivery of these nanoparticles into cells and animals. Crotamine forms nanoparticles with a variety of DNA and RNA molecules, and crotamine-plasmid DNA nanoparticles are selectively delivered into actively proliferating cells in culture or in living organisms such as mice, Plasmodium, and worms. As such, these nanoparticles could form the basis for a nucleic acid drug-delivery system. We also describe here the design and characterization of crotamine-functionalized gold nanoparticles, and the delivery of these nanoparticles into cells. We also evaluated the viability of using the combination of crotamine with silica nanoparticles in animal models, aiming to provide slow delivery, and to decrease the crotamine doses needed for the biological effects. In addition, the efficacy of administering crotamine orally was also demonstrated.


Assuntos
Antineoplásicos/administração & dosagem , Peptídeos Penetradores de Células/administração & dosagem , Venenos de Crotalídeos/administração & dosagem , Melanoma Experimental/tratamento farmacológico , Administração Oral , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Peptídeos Penetradores de Células/química , Peptídeos Penetradores de Células/farmacologia , Venenos de Crotalídeos/química , Venenos de Crotalídeos/farmacologia , DNA/metabolismo , Corantes Fluorescentes/química , Camundongos , Nanopartículas , RNA/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
3.
Nat Prod Res ; 34(17): 2533-2538, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30580611

RESUMO

We examined the ability of Bothrops jararaca venom (12.5 mg/kg) injected intraperitoneally (i.p.) to cause acute kidney injury (AKI) in rats. Blood urea and creatinine (AKI biomarkers, in g dL-1) were elevated after 2 h in venom-treated rats (urea: from 0.41 ± 0.1 to 0.7 ± 0.03; creatinine from 46.7 ± 3.1 to 85 ± 6.7; p < 0.05; n = 3 each), with no change in circulating reduced glutathione. Venom-treated rats survived for ∼6 h, at which point platelets were reduced (×103 µL-1; from 763.8 ± 30.2 to 52.5 ± 18.2) whereas leukocytes and erythrocytes were slightly increased (from 4.7 ± 0.3 to 6.6 ± 0.1 × 103 µL-1 and from 8.38 ± 0.1 to 9.2 ± 0.09 × 106 µL-1, respectively; p < 0.05); blood protein (5.2 ± 0.4 g dL-1) and albumin (2.7 ± 0.1 g dL-1) were normal, whereas blood and urinary urea and creatinine were increased. All parameters returned to normal with antivenom given 2 h post-envenomation. The i.p. injection of venom caused AKI similar to that seen with other routes of administration.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Bothrops , Venenos de Crotalídeos/efeitos adversos , Injúria Renal Aguda/sangue , Animais , Antivenenos/farmacologia , Antivenenos/uso terapêutico , Biomarcadores/sangue , Biomarcadores/urina , Creatinina/metabolismo , Venenos de Crotalídeos/administração & dosagem , Glutationa/metabolismo , Injeções Intraperitoneais , Masculino , Ratos
4.
PLoS Negl Trop Dis ; 12(8): e0006700, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30080908

RESUMO

The high medical importance of Crotalus snakes is unquestionable, as this genus is the second in frequency of ophidian accidents in many countries, including Brazil. With a relative less complex composition compared to other genera venoms, as those from the Bothrops genus, the Crotalus genus venom from South America is composed basically by the neurotoxin crotoxin (a phospholipase A2), the thrombin-like gyroxin (a serinoprotease), a very potent aggregating protein convulxin, and a myotoxic polypeptide named crotamine. Interestingly not all Crotalus snakes express crotamine, which was first described in early 50s due to its ability to immobilize animal hind limbs, contributing therefore to the physical immobilization of preys and representing an important advantage for the envenoming efficacy, and consequently, for the feeding and survival of these snakes in nature. Representing about 10-25% of the dry weight of the crude venom of crotamine-positive rattlesnakes, the polypeptide crotamine is also suggested to be of importance for antivenom therapy, although the contribution of this toxin to the main symptoms of envenoming process remains far unknown until now. Herein, we concomitantly performed in vitro and in vivo assays to show for the first time the dose-dependent response of crotamine-triggered hind limbs paralysis syndrome, up to now believed to be observable only at high (sub-lethal) concentrations of crotamine. In addition, ex vivo assay performed with isolated skeletal muscles allowed us to suggest here that compounds active on voltage-sensitive sodium and/or potassium ion channels could both affect the positive inotropic effect elicited by crotamine in isolated diaphragm, besides also affecting the hind limbs paralysis syndrome imposed by crotamine in vivo. By identifying the potential molecular targets of this toxin, our data may contribute to open new roads for translational studies aiming to improve the snakebite envenoming treatment in human. Interestingly, we also demonstrate that the intraplantal or intraperitoneal (ip) injections of crotamine in mice do not promote pain. Therefore, this work may also suggest the profitable utility of non-toxic analogs of crotamine as a potential tool for targeting voltage-gated ion channels in skeletal muscles, aiming its potential use in the therapy of neuromuscular dysfunctions and envenoming therapy.


Assuntos
Venenos de Crotalídeos/farmacologia , Membro Posterior , Músculo Esquelético/efeitos dos fármacos , Paralisia , Canais de Potássio de Abertura Dependente da Tensão da Membrana/metabolismo , Canais de Sódio Disparados por Voltagem/metabolismo , 4-Aminopiridina/administração & dosagem , 4-Aminopiridina/farmacologia , Animais , Venenos de Crotalídeos/administração & dosagem , Relação Dose-Resposta a Droga , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Medição da Dor , Canais de Potássio de Abertura Dependente da Tensão da Membrana/antagonistas & inibidores , Tetrodotoxina/administração & dosagem , Tetrodotoxina/farmacologia , Bloqueadores do Canal de Sódio Disparado por Voltagem/administração & dosagem , Bloqueadores do Canal de Sódio Disparado por Voltagem/farmacologia
5.
Sci Rep ; 8(1): 5057, 2018 03 22.
Artigo em Inglês | MEDLINE | ID: mdl-29567992

RESUMO

Crotamine, originally isolated from rattlesnake venom, has been extensively studied due to its pleiotropic biological properties, and special attention has been paid to its antitumor activity. However, long-term treatment with crotamine was accompanied by a reduction in animal body weight gain and by increases in glucose tolerance. As cancer is commonly associated with cachexia, to preclude the possible cancer cachexia-like effect of crotamine, herein this polypeptide was administered in healthy wild-type C57/BL6 mice by the oral route daily, for 21 days. Reduced body weight gain, in addition to decreased white adipose tissue (WAT) and increased brown adipose tissue (BAT) mass were observed in healthy animals in the absence of tumor. In addition, we observed improved glucose tolerance and increased insulin sensitivity, accompanied by a reduction of plasma lipid levels and decreased levels of biomarkers of liver damage and kidney disfunctions. Importantly, long-term treatment with crotamine increased the basal metabolic rate in vivo, which was consistent with the increased expression of thermogenic markers in BAT and WAT. Interestingly, cultured brown adipocyte cells induced to differentiation in the presence of crotamine also showed increases in some of these markers and in lipid droplets number and size, indicating increased brown adipocyte maturation.


Assuntos
Tecido Adiposo Marrom/efeitos dos fármacos , Tecido Adiposo Branco/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Venenos de Crotalídeos/administração & dosagem , Adipócitos/efeitos dos fármacos , Tecido Adiposo Marrom/metabolismo , Tecido Adiposo Branco/metabolismo , Animais , Metabolismo Basal/efeitos dos fármacos , Peso Corporal/fisiologia , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Teste de Tolerância a Glucose , Insulina/metabolismo , Rim/metabolismo , Rim/patologia , Fígado/metabolismo , Fígado/patologia , Camundongos , Termogênese/efeitos dos fármacos
6.
Am J Pathol ; 188(4): 863-875, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29353060

RESUMO

Proliferative glomerulonephritis is characterized by local inflammation and mesangial cell deterioration, followed by mesangial proliferation and glomerular healing. Parathyroid hormone-related peptide (PTHrP) is a mesangial cytokine-like growth factor implicated in mesangial proliferation and survival. No data are available about its role in glomerulonephritis. Herein, we analyzed the expression and role of PTHrP in glomerular inflammation and healing in an experimental model of glomerulonephritis induced by i.v. injection of Habu snake venom in mice. The temporal analysis showed marked renal damage in the first days after venom injection and the beginning of recovery within 7 days. Glomerular expression of PTHrP (transcript and protein) was observed in the early phase after venom injection (from day 1 to day 3), along with an inflammatory environment. The inactivation of secreted PTHrP with PTHrP-neutralizing antibody (PTH2E11; 120 µg i.p. daily) reduced the markers of local inflammation (expression of macrophage chemotactic protein-1; regulated upon activation, normal T cell expressed and secreted; cyclooxygenase 2; IL-6; and macrophage infiltration) and abolished the expression of PTHrP itself. Moreover, the glomerular cell proliferation was hampered, and the healing process was prevented on day 7 after venom injection. These results show that PTHrP has antinomic actions in glomerulonephritis, participating in both the proinflammatory condition and the healing process. Our work reveals the essential role of PTHrP in early glomerular repair in an experimental model of glomerulonephritis.


Assuntos
Glomerulonefrite/induzido quimicamente , Glomerulonefrite/metabolismo , Proteína Relacionada ao Hormônio Paratireóideo/metabolismo , Animais , Anticorpos Neutralizantes/farmacologia , Proliferação de Células/efeitos dos fármacos , Creatinina/sangue , Venenos de Crotalídeos/administração & dosagem , Glomerulonefrite/sangue , Glomerulonefrite/patologia , Inflamação/patologia , Injeções , Glomérulos Renais/patologia , Masculino , Camundongos Endogâmicos C57BL , Trimeresurus
7.
Amino Acids ; 50(2): 267-278, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29235017

RESUMO

The efficacy of crotamine as antitumoral was first demonstrated by daily intraperitoneal (IP) injections of low doses of this toxin in an animal model bearing melanoma tumors. Significant inhibition of tumor growth and increased lifespan of mice bearing tumor was also noticed after 21 consecutive days of this daily IP administration of crotamine. However, due to the limited acceptance of treatments by IP route in clinical conditions, herein, we evaluated the antitumor effect of this native polypeptide employing the oral route. The efficacy of crotamine in inhibiting the melanoma growth in vivo, even after passing through the gastrointestinal tract of the animal, was confirmed here. In addition, biochemical biomarkers and also histopathological analysis showed both the absence of any potential toxic effects in tissues or organs of the animal in which the highest accumulation of crotamine is expected. Interestingly, a reduction of weight gain was observed mainly in animals with tumor treated with crotamine by IP route, but not by oral administration. Albeit, oral administered crotamine was able to significantly decrease the body weight gain of healthy animals without tumor. Taking advantage of this same experimental animal models receiving crotamine by oral route, it was possible to show metabolic changes as the increased capacity of glucose clearance, which was accompanied by a reduction of the total cholesterol, and by increased high-density lipoprotein levels, both observed mainly in the absence of tumor. Triglycerides and low-density lipoprotein were also significantly decreased, but only in the absence of tumor. Taken together, these data suggest a clear trend for metabolic positive effects and mischaracterize unhealthy condition of animals, with or without tumors, treated with crotamine for 21 days. In addition, this study confirmed the efficacy of crotamine administered by oral route as antitumor agent, which besides the additional advantage of administration convenience and decreased risk of toxic effects, allowed the serendipitous observation of several positive metabolic effects on treated animals.


Assuntos
Venenos de Crotalídeos/administração & dosagem , Venenos de Crotalídeos/farmacologia , Melanoma Experimental/tratamento farmacológico , Metaboloma/efeitos dos fármacos , Venenos de Serpentes/química , Administração Oral , Sequência de Aminoácidos , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacologia , Antineoplásicos/toxicidade , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Venenos de Crotalídeos/toxicidade , Crotalus , Modelos Animais de Doenças , Camundongos , Camundongos Endogâmicos C57BL , Transplante de Neoplasias , Aumento de Peso/efeitos dos fármacos
8.
J Thromb Thrombolysis ; 44(4): 481-488, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28889321

RESUMO

While snake venom derived enzymes, such as the thrombin-like activity possessing ancrod, have been used to treat thrombotic disease by defibrinogenating patients, the therapeutic potential of fibrinogenolytic snake venom enzymes, such as those derived from Crotalus atrox, have not been fully explored. However, one of the potential risks of administering fibrinogenolytic enzymes to effect defibrinogenation is hemorrhage secondary to hypofibrinogenemia. The present investigation sought to determine if human fibrinogen modified with carbon monoxide (CO) and iron (Fe) could resist degradation by C. atrox venom as has been seen in vitro in a recently developed rabbit model of envenomation. Compared with unmodified human fibrinogen, CO/Fe modified fibrinogen administered prior to envenomation had significantly shorter onset of coagulation and greater strength; however, when administered after envenomation, there was no differences between the two types of fibrinogen. Of interest, when administered after envenomation, both types of fibrinogen delayed the onset of coagulation while increasing plasma clot strength, a mixed effect likely secondary to formation of fibrinogen degradation products. Further preclinical investigations are needed to further define the benefits and risks of the use of fibrinogenolytic enzymes as defibrinogenating agents, as well as the risks of the "biochemical brakes" used to modulate the activity or substrate of the fibrinogenolytic enzyme.


Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Venenos de Crotalídeos/farmacologia , Fibrinogênio/farmacologia , Animais , Monóxido de Carbono/química , Venenos de Crotalídeos/administração & dosagem , Crotalus , Fibrinogênio/administração & dosagem , Fibrinogênio/química , Fibrinogênio/uso terapêutico , Humanos , Ferro/química , Coelhos
9.
Zygote ; 24(1): 48-57, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25532535

RESUMO

The present study investigated the effects of crotamine, a cell-penetrating peptide from rattlesnake venom, at different exposure times and concentrations, on both developmental competence and gene expression (ATP1A1, AQP3, GLUT1 and GLUT3) of in vitro fertilized (IVF) bovine embryos. In Experiment 1, presumptive zygotes were exposed to 0.1 µM crotamine for 6, 12 or 24 h and control groups (vehicle and IVF) were included. In Experiment 2, presumptive zygotes were exposed to 0 (vehicle), 0.1, 1 and 10 µM crotamine for 24 h. Additionally, to visualize crotamine uptake, embryos were exposed to rhodamine B-labelled crotamine and subjected to confocal microscopy. In Experiment 1, no difference (P > 0.05) was observed among different exposure times and control groups for cleavage and blastocyst rates and total cells number per blastocyst. Within each exposure time, mRNA levels were similar (P > 0.05) in embryos cultured with or without crotamine. In Experiment 2, concentrations as high as 10 µM crotamine did not affect (P > 0.05) the blastocyst rate. Crotamine at 0.1 and 10 µM did not alter mRNA levels when compared with the control (P > 0.05). Remarkably, only 1 µM crotamine decreased both ATP1A1 and AQP3 expression levels relative to the control group (P < 0.05). Also, it was possible to visualize the intracellular localization of crotamine. These results indicate that crotamine can translocate intact IVF bovine embryos and its application in the culture medium is possible at concentrations from 0.1-10 µM for 6-24 h.


Assuntos
Blastocisto/efeitos dos fármacos , Blastocisto/fisiologia , Venenos de Crotalídeos/farmacologia , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Animais , Aquaporina 3/genética , Blastocisto/citologia , Bovinos , Venenos de Crotalídeos/administração & dosagem , Venenos de Crotalídeos/farmacocinética , Feminino , Fertilização in vitro , Transportador de Glucose Tipo 1/genética , Transportador de Glucose Tipo 3/genética , Masculino , ATPase Trocadora de Sódio-Potássio/genética
10.
Pharmacology ; 95(1-2): 78-86, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25633844

RESUMO

BACKGROUND/AIMS: To evaluate antileishmanial activity of crotamine, a toxin isolated from Crotalus durissus terrificus, in solution form and encapsulated in biodegradable microparticles in vitro. METHODS: Particles were analyzed on-chip by surface plasmon resonance and characterized by testing their diameters, zeta potential and encapsulation rate. The viability of promastigotes as well as murine macrophages was assessed. Furthermore, the phagocytic index was determined for macrophages, and cell supernatants were collected for the determination of TNF-α levels. An infection assay using Leishmania amazonensis-infected macrophages was also conducted. RESULTS: The diameters and zeta potential of control particles (1.35 µm; -12.3 mV) and of those containing crotamine (3.09 µm; -20.9 mV) were adequate for the assays conducted. Crotamine-loaded particles were better captured by macrophages than control particles (increase of 12% in the phagocytic index), leading to increased TNF-α levels (196 pg/ml), and they also induced a significant decrease in the numbers of amastigotes compared to infected macrophages only. CONCLUSION: The approach presented here opens the possibility of working with safe concentrations of encapsulated toxins to reach antileishmanial effects.


Assuntos
Antiprotozoários/farmacologia , Venenos de Crotalídeos/farmacologia , Leishmania/efeitos dos fármacos , Macrófagos Peritoneais/efeitos dos fármacos , Animais , Antiprotozoários/administração & dosagem , Venenos de Crotalídeos/administração & dosagem , Crotalus , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/farmacologia , Ácido Láctico/química , Macrófagos Peritoneais/metabolismo , Macrófagos Peritoneais/microbiologia , Masculino , Camundongos Endogâmicos BALB C , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Fator de Necrose Tumoral alfa/metabolismo
11.
In Vivo ; 28(5): 837-41, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25189897

RESUMO

The immune response modifier Canova® is a homeopathic remedy indicated for patients with depressed immune system, since this drug appears to increase adaptive immunity and induce an immune response against multiple and severe pathological conditions, including cancer. We evaluated the pattern of immune cellular response in non-human primates of the species Cebus apella exposed to N-methyl-N-nitrosourea (MNU) with and without Canova®. Twelve animals were divided into four groups, with three animals each: negative control and three experimental groups, MNU-alone (35 days); MNU (35 days)-plus-Canova® (3 days) and Canova®-alone (3 days). The animals received MNU orally and Canova® by three intravenous injections. Evaluation of the cellular immune response was performed by immunophenotyping of T-lymphocytes (CD4(+), CD8(+)), B-lymphocytes and natural killer cells. Analysis was also performed of the cell cycle. Our results suggest an increase of T-lymphocytes (CD4(+)CD3(+)) only in the Canova® group, while in the MNU-plus-Canova® group only B-lymphocytes increased.


Assuntos
Carcinógenos/toxicidade , Venenos de Crotalídeos/farmacologia , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/imunologia , Metilnitrosoureia/toxicidade , Extratos Vegetais/farmacologia , Animais , Antígenos de Superfície/metabolismo , Carcinógenos/administração & dosagem , Cebus , Ciclo Celular/efeitos dos fármacos , Venenos de Crotalídeos/administração & dosagem , Imunofenotipagem , Linfócitos/efeitos dos fármacos , Linfócitos/imunologia , Linfócitos/metabolismo , Metilnitrosoureia/administração & dosagem , Extratos Vegetais/administração & dosagem
12.
Braz. j. med. biol. res ; 45(6): 488-496, June 2012. ilus
Artigo em Inglês | LILACS | ID: lil-622781

RESUMO

We studied the effect of pulsed ultrasound therapy (UST) and antibothropic polyvalent antivenom (PAV) on the regeneration of mouse extensor digitorum longus muscle following damage by Bothrops jararacussu venom. Animals (Swiss male and female mice weighing 25.0 ± 5.0 g; 5 animals per group) received a perimuscular injection of venom (1 mg/kg) and treatment with UST was started 1 h later (1 min/day, 3 MHz, 0.3 W/cm², pulsed mode). Three and 28 days after injection, muscles were dissected and processed for light microscopy. The venom caused complete degeneration of muscle fibers. UST alone and combined with PAV (1.0 mL/kg) partially protected these fibers, whereas muscles receiving no treatment showed disorganized fascicules and fibers with reduced diameter. Treatment with UST and PAV decreased the effects of the venom on creatine kinase content and motor activity (approximately 75 and 48%, respectively). Sonication of the venom solution immediately before application decreased the in vivo and ex vivo myotoxic activities (approximately 60 and 50%, respectively). The present data show that UST counteracts some effects of B. jararacussu venom, causing structural and functional improvement of the regenerated muscle after venom injury.


Assuntos
Animais , Feminino , Masculino , Camundongos , Antivenenos/farmacologia , Bothrops , Venenos de Crotalídeos/intoxicação , Músculo Esquelético/efeitos dos fármacos , Mordeduras de Serpentes/terapia , Terapia por Ultrassom/métodos , Creatina Quinase/metabolismo , Venenos de Crotalídeos/administração & dosagem , Edema/induzido quimicamente , Fatores Imunológicos/imunologia , Atividade Motora/efeitos dos fármacos , Músculo Esquelético/enzimologia , Músculo Esquelético/patologia , Necrose , Teste de Desempenho do Rota-Rod , Regeneração/efeitos dos fármacos , Mordeduras de Serpentes/complicações
13.
Interact Cardiovasc Thorac Surg ; 14(1): 94-5, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22108918

RESUMO

We report the case of a 42-year old diabetic male presenting with erythema of the neck and anterior right thoracic region secondary to the application of an ointment derived from rattlesnakes, progressing to a full-blown necrotizing fasciitis in a short period of time, with associated mediastinitis, thrombocytopaenia and sepsis. The patient died despite aggressive multidisciplinary medical and surgical treatment. We present this case due to the unusual aetiology and fulminating course.


Assuntos
Venenos de Crotalídeos/efeitos adversos , Fasciite Necrosante/induzido quimicamente , Mediastinite/etiologia , Adulto , Venenos de Crotalídeos/administração & dosagem , Desbridamento , Fasciite Necrosante/complicações , Fasciite Necrosante/diagnóstico , Seguimentos , Humanos , Masculino , Mediastinite/diagnóstico , Mediastinite/cirurgia , Pomadas/efeitos adversos , Parede Torácica , Tomografia Computadorizada por Raios X
14.
Mol Pharm ; 9(2): 211-21, 2012 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-22142367

RESUMO

Our goal was to demonstrate the in vivo tumor specific accumulation of crotamine, a natural peptide from the venom of the South American rattlesnake Crotalus durissus terrificus, which has been characterized by our group as a cell penetrating peptide with a high specificity for actively proliferating cells and with a concentration-dependent cytotoxic effect. Crotamine cytotoxicity has been shown to be dependent on the disruption of lysosomes and subsequent activation of intracellular proteases. In this work, we show that the cytotoxic effect of crotamine also involves rapid intracellular calcium release and loss of mitochondrial membrane potential as observed in real time by confocal microscopy. The intracellular calcium overload induced by crotamine was almost completely blocked by thapsigargin. Microfluorimetry assays confirmed the importance of internal organelles, such as lysosomes and the endoplasmic reticulum, as contributors for the intracellular calcium increase, as well as the extracellular medium. Finally, we demonstrate here that crotamine injected intraperitoneally can efficiently target remote subcutaneous tumors engrafted in nude mice, as demonstrated by a noninvasive optical imaging procedure that permits in vivo real-time monitoring of crotamine uptake into tumor tissue. Taken together, our data indicate that the cytotoxic peptide crotamine can be used potentially for a dual purpose: to target and detect growing tumor tissues and to selectively trigger tumor cell death.


Assuntos
Sinalização do Cálcio/efeitos dos fármacos , Cálcio/metabolismo , Peptídeos Penetradores de Células/administração & dosagem , Venenos de Crotalídeos/administração & dosagem , Neoplasias/metabolismo , Animais , Antineoplásicos , Células CHO , Morte Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Peptídeos Penetradores de Células/farmacocinética , Cricetinae , Cricetulus , Venenos de Crotalídeos/farmacocinética , Crotalus , Retículo Endoplasmático/efeitos dos fármacos , Retículo Endoplasmático/metabolismo , Citometria de Fluxo , Células HEK293 , Humanos , Injeções Intraperitoneais , Lisossomos/efeitos dos fármacos , Lisossomos/metabolismo , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Camundongos , Camundongos Nus , Microscopia Confocal , Neoplasias/diagnóstico , Neoplasias/tratamento farmacológico , Tapsigargina/farmacologia , Células Tumorais Cultivadas , Ensaios Antitumorais Modelo de Xenoenxerto
15.
São Paulo; s.n; 2012. 83 p.
Tese em Português | LILACS, SES-SP, SESSP-IBPROD, SES-SP, SESSP-IBACERVO | ID: biblio-1080913

RESUMO

A esclerose múltipla é uma doença inflamatória crônica, de origem autoimune, que acarreta diversas alterações motoras, cognitivas e sensitivas. Dentre as alterações sensitivas, a dor é um dos graves problemas que afetam pessoas portadoras desta doença, interferindo com diversos aspectos da vida do paciente. É importante ressaltar que a esclerose múltipla não tem cura, sendo que a terapêutica se concentra nas ações que retardam a progressão da doença e promovem o alívio dos sintomas, melhorando a qualidade da vida do paciente...


Multiple sclerosis is a Central Nervous System Inflamatory demyelinating disease that has as primary symptomps losses of sensory, cognitive and motor functions. Among the sensory alternations, pain is one of the major concern, afecting various aspects of the patients lives...


Assuntos
Feminino , Camundongos , Crotalus/sangue , Crotoxina/administração & dosagem , Crotoxina/uso terapêutico , Esclerose Múltipla/induzido quimicamente , Venenos de Crotalídeos/administração & dosagem , Venenos de Crotalídeos/isolamento & purificação , Venenos de Crotalídeos/uso terapêutico , Encefalomielite , Encefalomielite Autoimune Experimental/fisiopatologia , Encefalomielite Autoimune Experimental/induzido quimicamente , Medição da Dor
16.
J Radiat Res ; 52(5): 557-67, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21952314

RESUMO

In this study we first evaluated the general radioprotective efficacy of Se, Zn and Mn (4 µg/ml each) plus Lachesis muta venom (4 ng/ml) combination (O-LM) by determining survival on rats irradiated with lethal doses of gamma-rays. The aim of the second part of the study was to investigate the O-LM ability to prevent ionizing radiation-induced damage on small intestine, bone marrow and submandibular glands. Hence, histological characteristics and functional studies, together with proliferation and apoptotic marker levels on whole body irradiated rats with a 5 Gy dose were evaluated. Results show that all animals of the untreated group died after whole body irradiation with 8 and 10 Gy while 60 day-survival was more than 80% and 40% in O-LM-treated animals, respectively. Histopathological examinations revealed a high degree of small intestine and submandibular gland radioprotection 3 days post-irradiation. O-LM inhibited histological damage on small intestine, restoring the radiation-induced reduction in villous height and crypt number. O-LM prevented radiation-induced loss of salivary gland function and morphological alterations. These effects were associated to a complete inhibition of radiation-induced apoptosis. Furthermore, studies performed 30 days post-irradiation revealed that O-LM significantly improved bone marrow repopulation, increasing all medullar progenies to the extent of the non-irradiated animals, and completely prevented permanent submandibular gland alterations. Based on the present results and taking into account that O-LM is being safely administered in phase I clinical trial as an immunomodulator, we conclude that O-LM is a non-toxic promising approach to achieve radioprotection for patients undergoing radiotherapy.


Assuntos
Protetores contra Radiação/farmacologia , Animais , Apoptose/efeitos dos fármacos , Apoptose/efeitos da radiação , Medula Óssea/efeitos dos fármacos , Medula Óssea/lesões , Medula Óssea/efeitos da radiação , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/efeitos da radiação , Venenos de Crotalídeos/administração & dosagem , Venenos de Crotalídeos/farmacologia , Raios gama/efeitos adversos , Humanos , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/lesões , Intestino Delgado/efeitos da radiação , Masculino , Manganês/administração & dosagem , Manganês/farmacologia , Lesões Experimentais por Radiação/patologia , Lesões Experimentais por Radiação/prevenção & controle , Protetores contra Radiação/administração & dosagem , Ratos , Ratos Sprague-Dawley , Selênio/administração & dosagem , Selênio/farmacologia , Glândula Submandibular/efeitos dos fármacos , Glândula Submandibular/lesões , Glândula Submandibular/efeitos da radiação , Zinco/administração & dosagem , Zinco/farmacologia
17.
PLoS One ; 6(7): e21988, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21811552

RESUMO

The evolution of gastric carcinogenesis remains largely unknown. We established two gastric carcinogenesis models in New-World nonhuman primates. In the first model, ACP03 gastric cancer cell line was inoculated in 18 animals. In the second model, we treated 6 animals with N-methyl-nitrosourea (MNU). Animals with gastric cancer were also treated with Canova immunomodulator. Clinical, hematologic, and biochemical, including C-reactive protein, folic acid, and homocysteine, analyses were performed in this study. MYC expression and copy number was also evaluated. We observed that all animals inoculated with ACP03 developed gastric cancer on the 9(th) day though on the 14(th) day presented total tumor remission. In the second model, all animals developed pre-neoplastic lesions and five died of drug intoxication before the development of cancer. The last surviving MNU-treated animal developed intestinal-type gastric adenocarcinoma observed by endoscopy on the 940(th) day. The level of C-reactive protein level and homocysteine concentration increased while the level of folic acid decreased with the presence of tumors in ACP03-inoculated animals and MNU treatment. ACP03 inoculation also led to anemia and leukocytosis. The hematologic and biochemical results corroborate those observed in patients with gastric cancer, supporting that our in vivo models are potentially useful to study this neoplasia. In cell line inoculated animals, we detected MYC immunoreactivity, mRNA overexpression, and amplification, as previously observed in vitro. In MNU-treated animals, mRNA expression and MYC copy number increased during the sequential steps of intestinal-type gastric carcinogenesis and immunoreactivity was only observed in intestinal metaplasia and gastric cancer. Thus, MYC deregulation supports the gastric carcinogenesis process. Canova immunomodulator restored several hematologic measurements and therefore, can be applied during/after chemotherapy to increase the tolerability and duration of anticancer treatments.


Assuntos
Cebus , Modelos Animais de Doenças , Neoplasias Experimentais/patologia , Neoplasias Gástricas/patologia , Animais , Linhagem Celular , Venenos de Crotalídeos/administração & dosagem , Venenos de Crotalídeos/farmacologia , Dosagem de Genes/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Metilnitrosoureia , Neoplasias Experimentais/diagnóstico por imagem , Neoplasias Experimentais/genética , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacologia , Proteínas Proto-Oncogênicas c-myc/genética , Proteínas Proto-Oncogênicas c-myc/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/genética , Ultrassonografia
18.
J Radiat Res ; 50(6): 537-44, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19823008

RESUMO

In this study we evaluated in vivo the tolerance induced by the combination of Se, Zn and Mn (4 microg/ml each) plus Lachesis muta venom (4 ng/ml) (O-LM) to high doses of ionizing radiation. The protective effect of O-LM was investigated on the small-intestine and bone marrow of mice irradiated with a single whole-body dose of 10 Gy employing a (137)Cs source. Mice were sacrificed 3 days after irradiation. Mice receiving a subcutaneous daily O-LM injection starting 30 days before irradiation, showed a higher number of crypts, enhanced villous conservation and lack of edema or vascular damage in comparison to the untreated and irradiated group. In addition, O-LM treatment decreased vascular damage and the grade of aplasia preserving medullar progenies induced by ionizing radiation on mouse bone marrow. The protective effect of O-LM against radiation injury to the small intestine was associated with an increase in proliferation and a reduction of apoptosis in intestinal crypts and furthermore, to an enhanced intestinal immunoreactivity of MnSOD, and CuZnSOD, and also catalase. Based on the present results and taking into account that O-LM is being safely administered in phase I clinical trial as an immunomodulator, we suggest that O-LM could be an attractive candidate as a safe radioprotective agent for patients undergoing radiotherapy.


Assuntos
Medula Óssea/efeitos dos fármacos , Medula Óssea/patologia , Medula Óssea/efeitos da radiação , Venenos de Crotalídeos/administração & dosagem , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/efeitos da radiação , Metais Pesados/administração & dosagem , Irradiação Corporal Total/efeitos adversos , Animais , Combinação de Medicamentos , Intestino Delgado/patologia , Camundongos , Camundongos Nus , Tolerância a Radiação/efeitos dos fármacos , Protetores contra Radiação/administração & dosagem
19.
Mediators Inflamm ; 2008: 874962, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18604304

RESUMO

The effects of Crotalus durissus terrificus venom (Cdt) were analyzed with respect to the susceptibility and the inflammatory mediators in an experimental model of severe envenomation. BALB/c female mice injected intraperitoneally presented sensibility to Cdt, with changes in specific signs, blood biochemical and inflammatory mediators. The venom induced reduction of glucose and urea levels and an increment of creatinine levels in serum from mice. Significant differences were observed in the time-course of mediator levels in sera from mice injected with Cdt. The maximum levels of IL-6, NO, IL-5, TNF, IL-4 and IL-10 were observed 15 min, 30 min, 1, 2 and 4 hours post-injection, respectively. No difference was observed for levels of IFN-gamma. Taken together, these data indicate that the envenomation by Cdt is regulated both pro- and anti-inflammatory cytokine responses at time-dependent manner. In serum from mice injected with Cdt at the two first hours revealed of pro-inflammatory dominance. However, with an increment of time an increase of anti-inflammatory cytokines was observed and the balance toward to anti-inflammatory dominance. In conclusion, the observation that Cdt affects the production of pro- and anti-inflammatory cytokines provides further evidence for the role played by Cdt in modulating pro/anti-inflammatory cytokine balance.


Assuntos
Venenos de Crotalídeos/toxicidade , Crotalus/metabolismo , Citocinas/sangue , Animais , Creatina/sangue , Venenos de Crotalídeos/administração & dosagem , Modelos Animais de Doenças , Feminino , Interleucina-10/sangue , Interleucina-4/sangue , Interleucina-6/sangue , Cinética , Camundongos , Camundongos Endogâmicos BALB C , Óxido Nítrico/sangue , Mordeduras de Serpentes/sangue , Mordeduras de Serpentes/induzido quimicamente , Fator de Necrose Tumoral alfa/sangue
20.
Biochem Biophys Res Commun ; 369(2): 753-60, 2008 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-18312855

RESUMO

Agglucetin, a platelet glycoprotein (GP)Ib binding protein from Formosan Agkistrodon acutus (A. acutus) venom, could sustain human umbilical vein endothelial cell (HUVEC) proliferation and HUVEC adhering to immobilized agglucetin showed extensive spreading, which was strongly abrogated by integrin antagonists 7E3 and triflavin. Flow cytometric analyses confirmed the expression of GPIb complex on HUVEC is absent and fluorescein isothiocyanate (FITC)-agglucetin binds to HUVEC in a dose-dependent and saturable manner. Furthermore, native agglucetin specifically and dose-dependently inhibited the binding of FITC-23C6, an anti-alphavbeta3 monoclonal antibody (mAb), but not antibodies against alpha2 and alpha5, toward HUVEC and purified alphavbeta3 also bound to immobilized agglucetin-beta in a dose-dependent manner. Moreover, agglucetin exhibited a pro-angiogenic effect in vitro, as well as the focal adhesion kinase (FAK)-associated signaling molecules responsible for HUVEC activation were initiated by agglucetin. In conclusion, agglucetin, acting as a survival factor, promotes endothelial adhesion and angiogenesis by triggering alphavbeta3 signaling through FAK/phosphatidylinositol 3-kinase (PI3K)/Akt pathway.


Assuntos
Venenos de Crotalídeos/administração & dosagem , Células Endoteliais/fisiologia , Integrina alfaVbeta3/metabolismo , Neovascularização Fisiológica/fisiologia , Transdução de Sinais/fisiologia , Indutores da Angiogênese/administração & dosagem , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Dimerização , Relação Dose-Resposta a Droga , Células Endoteliais/citologia , Células Endoteliais/efeitos dos fármacos , Humanos , Lectinas Tipo C/administração & dosagem , Neovascularização Fisiológica/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA